Cengiz Beyan

Cengiz Beyan

Auto-generated profile, based on publicly available information

Cengiz Beyan

Hematology, Faculty of Medicine, Ufuk University, Cankaya, Turkey

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
CBCengiz Beyan
Cengiz Beyan
EBEsin Beyan
Esin Beyan
Recently, several studies about mean platelet volume (MPV) changes in various pathological conditions were published. The aim of this study was to evaluate the accuracy of the measurement in these studies. The study was performed using the data of 181 studies containing a healthy control groups within 1181 studies about MPV indexed PubMed database since 2012. A total of 81 studies were included retrospectively. The distributions of sex, age, and platelet counts were not reported in 16, 12, and 28 studies, respectively. Type of anticoagulant was not noted in 60 studies. The technology used was not specified in 36 studies. The MPV values measured with Sysmex were significantly higher than measured with Beckman Coulter, Abbott CELL-DYN, and Siemens ADVIA. The MPV measurements varied up to 17.8% by the instruments. The measurement times between 15 min and 2 h was significantly different from the measurement times less than 15 min and more than 2 h. The MPV measurement times from venipuncture were not indicated in 86 studies (47.5%). Maximum deviations in MPV measurements by the MPV measurement times and plus the instruments used varied up to 17.8 and 27.7%, respectively. Both the MPV measurement times and instruments used were not stated in 29 studies (16.0%). Only 47 prospective studies (26.0%) enlightened about the type of anticoagulant, instruments used for MPV measurement, MPV measurement time, platelet counts, and MPV values. As a result, the measurements were not standardized sufficiently in published studies about MPV. It may be explained that the differences between the results of studies made the same pathological conditions.

1 August 2003 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
EBE Beyan
E Beyan
CBC Beyan
C Beyan
ADA Demirezer
A Demirezer
EEE Ertuğrul
E Ertuğrul
AUA Uzuner
A Uzuner
Objective: The aim of this study is to investigate the relationship between serum ferritin levels and disease activity in patients with systemic lupus erythematosus (SLE). Methods: Serum ferritin levels of 72 SLE patients were measured. The SLE patients were subdivided into two groups according to SLE disease activity index (SLEDAI) as ≤10 and ≥11. The results were compared with 31 patients with rheumatoid arthritis (RA). 36 patients among 72 with SLE were evaluated before and after treatment. Results: Serum levels of ferritin in SLE patients were higher than RA patients (p<0,001). There was a significant difference in ferritin levels before and after treatment. The levels of ferritin in SLE were positively correlated with SLEDAI scores. Patients with SLEDAI scores ≥11 had significantly higher serum ferritin levels. Conclusion: Serum ferritin levels may be a useful marker of disease activity in SLE patients.

1 August 2003 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
CBCengiz Beyan
Cengiz Beyan
TÇTürker Çetin
Türker Çetin
KKKürb̧at Kaptan
Kürb̧at Kaptan
ONOral Nevruz
Oral Nevruz

1 October 2007 in Hematology
Verified
Journal Article
Closed access
KKKürşat Kaptan
Kürşat Kaptan
AIAhmet Ifran
Ahmet Ifran
CBCengiz Beyan
Cengiz Beyan
DSDurdu Sertkaya
Durdu Sertkaya
RhG-CSF is increasingly used for stimulation of granulopoiesis and stem cell mobilization in healthy donors for allogeneic stem cell transplantation. However, a possible association between thrombosis and rhG-CSF administration has been reported. For that reason, in this study, we investigated the effect of rhG-CSF on platelet aggregation in whole blood of 10 healthy volunteers. Three concentrations of rhG-CSF solution (1, 10 and 100 ng/ml) were prepared. Each concentration of rhG-CSF solution and a control diluent without rhG-CSF were incubated with whole blood. Incubation with rhG-CSF solutions would result in 0.1, 1.0 and 10 ng/ml rhG-CSF concentrations in the blood. After incubation, aggregation responses were evaluated with ADP (5 and 10 μM) and collagen (2 and 5 μg/ml) in whole blood. When compared to control, preincubation with all dilutions of rhG-CSF augmented aggregation of platelets induced by ADP and collagen in a statistically significant manner (p < 0.05 for all comparisons). There was also a relationship between rhG-CSF concentration (1, 10 and 100 ng/ml) and augmentation of platelet aggregation response (p < 0.0001 for 5–10 μM ADP; p < 0.0001 for 2–5 μg/ml collagen). In conclusion, this study with an in vitro model showed that rhG-CSF administration may lead to platelet hyperaggregability.

1 February 2006 in Clinical and Laboratory Haematology
Verified
Journal Article
Closed access
PDF file
CBC. Beyan
C. Beyan
KKK. Kaptan
K. Kaptan
AIA. Ifran
A. Ifran
SSS. Savasci
S. Savasci
YOY. Ozturk
Y. Ozturk
BOB. Okmen
B. Okmen

31 August 2005 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
CBCengiz Beyan
Cengiz Beyan
KKKürşat Kaptan
Kürşat Kaptan
SSSerap Savaşçı
Serap Savaşçı
AIAhmet Ifran
Ahmet Ifran
YÖYeşim Öztürk
Yeşim Öztürk
BÖBirgül Ökmen
Birgül Ökmen